In a significant move in the biopharmaceutical sector, Banco Santander S.A. substantially increased its investment in Regeneron Pharmaceuticals, Inc. during the first quarter. This strategic acquisition underscores the Spanish multinational financial services company’s growing confidence in the biotechnology giant, making headlines across financial markets.
According to its latest filing with the SEC, Banco Santander S.A. expanded its holdings in Regeneron Pharmaceuticals by an impressive 58.5%. The institutional investor now possesses a total of 11,852 shares of the biopharmaceutical company’s stock, following the purchase of an additional 4,374 shares within the quarter. This substantial share acquisition represents a notable commitment to the pharmaceutical stock.
The value of Banco Santander S.A.’s holdings in Regeneron Pharmaceuticals stood at a remarkable $7,517,000 as of its most recent SEC filing, highlighting the considerable financial weight of this investment. Such a significant stake by a major bank often signals a strong belief in the future performance of the underlying asset.
Beyond Banco Santander, several other institutional investors and hedge funds have also been active in trading Regeneron Pharmaceuticals shares. For instance, Pinney & Scofield Inc. acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter, an investment valued at approximately $25,000.
Similarly, E Fund Management Hong Kong Co. Ltd. significantly increased its stake in Regeneron Pharmaceuticals shares by an impressive 344.4% during the first quarter. This firm now holds 40 shares of the biopharmaceutical company’s stock, valued at $25,000, after purchasing an additional 31 shares during the same period. Other new positions were established by Tompkins Financial Corp ($32,000), Curat Global LLC ($32,000), and American National Bank & Trust ($44,000) during the first quarter.
Collectively, hedge funds and other institutional investors now own a substantial 83.31% of Regeneron Pharmaceuticals’ stock, indicating a broad institutional interest in this biopharmaceutical company. This high level of institutional ownership often suggests stability and confidence in a company’s prospects.
Brokerages have also been actively weighing in on REGN’s outlook. Royal Bank Of Canada recently downgraded Regeneron Pharmaceuticals from a “moderate buy” to a “hold” rating, setting a target price of $662.00. Robert W. Baird also adjusted its stance, cutting their target price from $759.00 to $652.00 while maintaining a “neutral” rating on the stock.
Further brokerage insights include Cantor Fitzgerald initiating coverage with an “overweight” rating and a $695.00 target price. UBS Group reissued a “neutral” rating, while The Goldman Sachs Group reduced their price objective from $917.00 to $804.00 but maintained a “buy” rating. Overall, MarketBeat data indicates a consensus rating of “Moderate Buy” for Regeneron Pharmaceuticals, with an average target price of $837.61, reflecting varied but generally positive sentiment among analysts.
